Features | Partner Sites | Information | LinkXpress
Sign In
Schiller
Ampronix
ElsMed

Simplified Alzheimer’s Disease Diagnosis Using PET Imaging and More Effective Criteria

By Medimaging International staff writers
Posted on 24 Jul 2014
According to French investigators, over one-third of patients receive an incorrect diagnosis of Alzheimer’s disease (AD). To reduce the number of errors, the diagnostic criteria available must be the most reliable possible, especially at the very early stages of the disease. For the past 10 years, an international team of neurologists has been working towards this objective. The researchers recently introduced new diagnostic criteria, in particular, biomarkers. These are authentic signatures of the disease, and are present from the first symptoms (prodromal stage).

In the June 2014 issue of the Lancet Neurology journal, Dr. Bruno Dubois, from the National de la Santé et de la Recherche Médicale (Inserm; Paris, France) and Pierre and Marie Curie University (Paris, France) /AP-HP Joint Research Unit 975) and colleagues have developed a simplified diagnosis based on the most specific criteria of the disease, which should have a major impact in clinical practice.

AD is the most common (70%) form of dementia. The real challenge of a definitive diagnosis is to know how to differentiate this disease from other types of dementia, and establish the diagnosis as effectively and as early as possible.

In 2005, an international group of neurologists, coordinated by Inserm’s Dr. Bruno Dubois, came together to redefine the diagnostic criteria established in 1984. Up to then, it had been necessary to await the death of a patient in order to establish a diagnosis of AD with certainty by examining the lesions in his/her brain. And in the living, only a probability of disease could be inferred, and only at a late stage, based on a certain threshold of severity of dementia.

In 2007, the international team broke these hypotheses apart. The researchers introduced new diagnostic criteria, particularly biomarkers. These are authentic signatures of the disease, and are present from the initial symptoms (prodromal stage). The publication of these findings initiated a transformation. Researchers then observed that with these new criteria, “36% of their patients included in a therapeutic trial based on previous clinical criteria did not have Alzheimer’s disease,” reported Prof. Dubois. However, although this analysis involved only a subgroup of patients, the implications are serious. Patients did not receive the correct treatment and/or care. Moreover, flawed patient selection might have had an impact on the lack of efficacy observed for the new treatment.

Since 2007, many studies have been published. The international group decided to analyze this literature to make the diagnostic algorithm for AD simpler and more reliable. “We have reached the end of the road; we have arrived at the essence, something refined, resulting from an international consensus,” indicated Prof. Dubois. The diagnosis of Alzheimer’s disease will henceforth rely on “just a couple of clinical-biological criteria for all stages of the disease.”

Most of the time, the diagnosis of AD is based primarily on a suggestive clinical picture. It is subsequently confirmed or rejected using a biomarker. As regards the clinical picture, there are three scenarios: (1) typical cases (80%–85% of all cases): impairment of episodic long-term memory (known as amnestic syndrome of the hippocampal type and corresponding to difficulty remembering a list a words, even with clues, for example); (2) atypical cases (15%–20% of cases): atrophy of the posterior part of the cerebral cortex or logopenic aphasia (impairment of verbal memory where the patient inverts the syllables of a word when repeating it, for example), or frontal brain damage, which results in behavioral problems; (3) preclinical states: asymptomatic at-risk (patients without symptoms, but who are fortuitously discovered to have positive biomarkers during scientific studies), and presymptomatic (with a genetic mutation).

One of the following two biomarkers is required: (1) in the cerebrospinal fluid (obtained by lumbar puncture) to ascertain abnormal levels of brain proteins (reduced beta amyloid protein and increased tau protein); (2) and in the brain by positron emission tomography (PET) neuroimaging to determine the elevated retention of amyloid tracer.

This simpler and more effective algorithm is important, mainly for research (therapeutic trials, characterization of the disease, monitoring of patient cohorts), according to the investigators. Outside of research, the use of biomarkers, which is expensive and/or invasive, currently remains limited to young patients or difficult or complex cases in specialty centers.

Related Links:
National de la Santé et de la Recherche Médicale
Pierre and Marie Curie University




Channels

Radiography

view channel

Analysis Tool Shows Proton Therapy Less Expensive Than IMRT for Advanced Head and Neck Cancers

The episodic cost of care using intensity-modulated proton therapy (IMPT) in advanced stage head and neck cancer is less expensive than intensity-modulated radiotherapy (IMRT), according to new findings. The new proof-of-concept study uses a cost analysis tool that can be used to outline the value of competing healthcare... Read more

MRI

view channel

Dyslexic Patients Shown to Have Disordered Network Connections in the Brain

Scientists conducted a whole-brain functional connectivity analysis of dyslexia using functional magnetic resonance imaging (fMRI), and revealed how brain activity is disordered in dyslexic patients. Dyslexia is a neurologic reading disability that occurs when the regions of the brain that process written language do... Read more

General/Advanced Imaging

view channel
Image: From left, Guy Genin, PhD, John Boyle and Stavros Thomopoulos, PhD, watch as a sample is exposed to stress and force. They have developed algorithms that may lead to the ability to identify weak spots in tendons, muscles and bones (Photo courtesy of Washington University in St. Louis).

Image Analysis Algorithms Devised to Find Weak Spots in Muscles, Tendons, and Bones prone to Tearing, Breaking

Researchers have developed algorithms to detect weak spots in muscles, tendons, and bones predisposed to tearing or breaking. The technology, which needs to be further refined before it is used in patients,... Read more

Imaging IT

view channel

Interactive Dashboard and Visualization Tool Designed for Oncologists

A new tool has been developed to help users of an information system for radiation oncology to analyze data and use metrics to help make more informed decisions. Varian Medical Systems (Palo Alto CA, USA), a developer of cancer treatment technology and informatics software for managing comprehensive cancer clinics, will... Read more

Industry News

view channel

USD 12 Billion Out of Total Spent on Medical Imaging Squandered in the US

The United States wastes close to USD 12 billion on unnecessary medical imaging yearly, according to a new survey of 196 hospital leaders. Smart data company peer60 (American Fork, UT, USA) surveyed 196 healthcare leaders about medical imaging in less than two weeks and found a number of reasons for the squandered resources.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.